Personalized briefing
Discovery of the day · Neurology
Lecanemab use in Chinese patients with Alzheimer’s disease: a 12‐month multicenter real‐world study
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
This multicenter real-world study of 1,042 Chinese Alzheimer’s disease patients receiving lecanemab demonstrated favorable 12-month safety, with amyloid-related imaging abnormalities occurring in only 7.87% and infusion-related reactions in 16.12%. Cognitive outcomes, measured by Clinical Dementia Rating Scale–Sum of Boxes, showed no decline at 12 months across the overall cohort or any subgroup, while blood-based biomarkers were the sole AD biomarker assay in 5.28% of patients with comparable outcomes. These findings validate lecanemab’s real-world effectiveness in diverse populations and support the potential of blood-based biomarkers to guide treatment — clinically meaningful evidence that advances the translational neuropharmacology and biomarker research central to your work in improving patient well-being.
Novelty
74%
Rigor
83%
Significance
81%
Validity
86%
Clarity
90%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
